Source: Annual Congress 2009 - PG7 Drug-induced pulmonary toxicity



Rating:

Share or cite this content

Citations should be made in the following way:
Ph. Camus (Dijon, France). Drug-induced pulmonary toxicity in clinical practice. Annual Congress 2009 - PG7 Drug-induced pulmonary toxicity

Member's Comments

No comment yet.

Related content which might interest you: Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences Source: Eur Respir Rev 2015; 24: 420-427 Year: 2015 The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art Year: 2008 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice Source: Eur Respir J 2013; 42: 689-700 Year: 2013 Impact of guidelines for the management of pulmonary embolism in clinical practice Source: International Congress 2019 – Breathing disorders, cardiovascular disease and pulmonary embolism guidelines Year: 2019 Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019 Year: 2019 Pulmonary hemodynamics and clinical manifestations of COPD patients: is there a relationship? Source: Virtual Congress 2020 – Investigations of COPD Year: 2020 Importance of cardiac biomarkers in the evaluation of acute pulmonary thromboembolism severity, mortality and complicated clinical course Source: Annual Congress 2011 - New insights in management of interstitial and vascular lung diseases Year: 2011 Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018 Management of sarcoidosis in clinical practice Source: Eur Respir Rev 2016; 25: 141-150 Year: 2016 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: 243-244 Year: 2002 Pulmonary function tests in clinical practice Source: Annual Congress 2013 –PG17 Diagnostic tests for paediatric pulmonologists Year: 2013 Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice Source: Eur Respir Rev, 26 (146) 170094; 10.1183/16000617.0094-2017 Year: 2017 Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017 Year: 2017 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 Pulmonary infiltrates in patients with malignancies: why and how neutropenia influences clinical reasoning Source: Eur Respir J 2009; 33: 6-8 Year: 2009 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Severe sarcoidosis: clinical features and management Source: Virtual Congress 2021 – Rare lung diseases 2021 Year: 2021